Chetasi Talati

Internal Medicine
12902 Usf Magnolia Dr
Tampa, FL 33612

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications

Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML.

Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML.

Journal: Blood advances
Published: July 11, 2023

Molecular characteristics and outcomes in Hispanic and non-Hispanic patients with acute myeloid leukemia.

Molecular characteristics and outcomes in Hispanic and non-Hispanic patients with acute myeloid leukemia.

Journal: EJHaem
Published: September 16, 2022

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma.

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 27, 2022

Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies.

Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies.

Journal: Blood advances
Published: May 23, 2022

Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations.

Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations.

Journal: Cancer
Published: May 13, 2022

Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia.

Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia.

Journal: Blood
Published: April 13, 2022

CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia.

CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia.

Journal: Clinical lymphoma, myeloma & leukemia
Published: March 17, 2022

SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity.

SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity.

Journal: Haematologica
Published: December 07, 2021

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.

Journal: Blood cancer journal
Published: October 17, 2021

Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts.

Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts.

Journal: Leukemia
Published: July 27, 2021

MYC overexpression is associated with an early disease progression from MDS to AML.

MYC overexpression is associated with an early disease progression from MDS to AML.

Journal: Leukemia research
Published: July 26, 2021

Galinpepimut-S (GPS): an investigational agent for the treatment of acute myeloid leukemia.

Galinpepimut-S (GPS): an investigational agent for the treatment of acute myeloid leukemia.

Journal: Expert opinion on investigational drugs
Published: May 31, 2021
Showing 1-12 of 49

Last Updated: 09/26/2026